SRPT (Sarepta) Quick DD – Why Elevidys Still Matters
Saw this Yahoo article on SRPT and Elevidys, so I did a quick dive. I only have a small position and this is not financial advice, just sharing my thoughts.
Sarepta focuses on rare diseases, mainly Duchenne Muscular Dystrophy (DMD). Their flagship product is Elevidys, currently the only FDA-approved gene therapy for DMD.
In Q1 2026 they reported strong total revenue of $731 million thanks to partnership payments, even though Elevidys sales came in at $102 million (down from previous quarters due to the recent label update and safety concerns). The Japan launch also brought in a $40 million milestone. Management kept their full-year product revenue guidance at $1.2B – $1.4B.
The story is still interesting because Elevidys remains the only approved gene therapy in this space, and longer-term data continues to show it can slow disease progression. Japan is already contributing, and the company expects US sales momentum to pick up again in the second half of 2026 and into 2027. They’re also running new studies with improved immunosuppression protocols to potentially expand access later.
That said, the safety issues have narrowed the label to ambulatory patients only, which hurt near-term sales. Like most biotech stocks, SRPT is volatile and carries high risk, especially with the regulatory and commercial uncertainties around gene therapy.
Overall, 2026 feels like a reset year. If confidence returns and the data keeps holding up, there’s decent upside potential here. If the safety concerns linger, it could stay pressured.
Worth keeping an eye on if you follow the biotech/DMD space.
DYOR,